Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Pomalidomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pomalidomide | Pomalyst | CC-4047 | Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Kaposi's sarcoma | not applicable | Pomalidomide | FDA approved | Actionable | In a Phase I/II trial (12-C-0047) that supported FDA approval, Pomalyst (pomalidomide) treatment was well-tolerated and resulted in an objective response rate (ORR) of 73% (16/22) in patients with Kaposi's sarcoma, including HIV-positive patients who failed HAART (ORR 60%, 9/15) and HIV-negative patients (ORR 100%, 7/7) (PMID: 27863194; NCT01495598). | 27863194 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01998971 | Phase I | Pomalidomide Bortezomib + Dexamethasone Melphalan Thalidomide Lenalidomide Prednisone Daratumumab Carfilzomib Diphenhydramine Montelukast | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | Active, not recruiting | USA | 2 |
NCT02343042 | Phase Ib/II | Bortezomib Dexamethasone + Selinexor Pomalidomide | Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma | Recruiting | USA | CAN | 0 |
NCT02576977 | Phase III | Pomalidomide Pembrolizumab Dexamethasone | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | Terminated | 0 | |
NCT02616640 | Phase I | Pomalidomide Dexamethasone Durvalumab | A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 5 |
NCT02188368 | Phase II | Bortezomib + Carfilzomib + Clarithromycin Pegylated liposomal-doxorubicin + Pomalidomide Pomalidomide | Pomalidomide for Lenalidomide for Failures | Active, not recruiting | USA | 0 |
NCT02400242 | Phase I | Citarinostat Dexamethasone Pomalidomide | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | Active, not recruiting | USA | 4 |
NCT01734928 | Phase III | Pomalidomide Bortezomib + Dexamethasone | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 20 |